Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18045044 | 0.98 | NOS2 (0.57) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL11281217 | 0.82 | NOS2 (0.53) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL11281212 | 0.82 | NOS2 (0.53) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL22068858 | 0.79 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL22068857 | 0.79 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL104888 | 0.79 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL8983137 | 0.79 | NOS2 (0.50) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL14291059 | 0.76 | NOS2 (0.96) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL20675953 | 0.76 | NOS2 (0.96) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL6191953 | 0.76 | NOS2 (0.61) | NOS2GRIN2BGRIN1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066070-B1 | CATALYTIC HYDROGENATION FOR THE PREPARATION OF AMINES FROM AMIDE ACETALS, KETENE-N, O-ACETALS OR ESTERIMIDES | EVONIK DEGUSSA GMBH (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3066070-A1 | CATALYTIC HYDROGENATION FOR THE PREPARATION OF AMINES FROM AMIDE ACETALS, KETENE N,O-ACETALS OR ESTER IMIDES | Evonik Degussa GmbH (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067448-A1 | CATALYTIC HYDROGENATION FOR THE PREPARATION OF AMINES FROM AMIDE ACETALS, KETENE N,O-ACETALS OR ESTER IMIDES | EVONIK INDUSTRIES AG (DE) | 2015-05-14 | — | — | WO | disclosed |
| EP-2868652-A1 | Catalytic hydrogenation for the preparation of amines from amide acetals, ketene-N, O-acetals or esterimides | Evonik Industries AG (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | NOS2 3471/4885GRIN2B 1740/4885GRIN1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.